{"filings":[{"id":721997,"accession_number":"0001193125-26-245235","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2026-05-28T20:11:17+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Guardian Pharmacy amends credit agreement, extending maturity to 2030 and increasing capacity to $80M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of revolving loan commitments extended from April 23, 2027 to May 21, 2030.","Company may add up to $40M in incremental term loans, bringing total borrowing capacity to $80M.","Consolidated leverage ratio replaced with consolidated net leverage ratio; cash up to $20M subtracts from debt.","Amendment reflects borrower's public company status and updates various baskets and thresholds.","Involves multiple guarantor subsidiaries and lenders including Regions Bank, Bank of America, Huntington."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95562,"accession_number":"0001193125-26-211924","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guardian Pharmacy holds 2026 annual meeting; all proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders re-elected directors John Ackerman and Randall Lewis to Class II for three-year terms.","Say-on-pay advisory vote approved with 53.8M for vs 500K against (98.9% support).","Stockholders selected 1-year frequency for future say-on-pay votes; board will hold annual votes.","Ratification of Ernst & Young as independent auditor for 2026 approved by 55.1M votes.","About 910K broker non-votes on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95561,"accession_number":"0001193125-26-208989","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Q1 revenue $336.6M (+2% YoY); raises FY Adjusted EBITDA guidance to $123-127M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $336.6M (+2% YoY); residents served 207K (+10% YoY). Net income $13.5M vs $9.3M.","Adjusted EBITDA $29.8M vs $23.4M; diluted EPS $0.21, adjusted EPS $0.29.","FY 2026 guidance: revenue unchanged $1.40-1.42B; Adjusted EBITDA raised to $123-127M from $120-124M.","Cash $64.9M, no debt on credit facility; completed non-dilutive secondary offering of 6.9M shares in March 2026.","Company offset IRA pricing resets, maintaining margin stability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":336595000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108714,"accession_number":"0001193125-26-119772","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Guardian Pharmacy completes $31/share synthetic secondary; loses controlled company status","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company sold 1,020,000 new shares at $31 in public offering; used proceeds to buy 1,020,000 shares from holders, cancelling them; no net share change.","Selling stockholders (Bindley Capital, Cardinal Equity, etc.) sold 5,880,000 shares; company received no proceeds from that portion.","Selling stockholders no longer hold majority voting power; Guardian ceases to be a controlled company under NYSE rules as of March 20, 2026.","Board established Nominating and Governance Committee with independent members Cosler, Lewis, Patchett effective March 20, 2026.","Stock Purchase Agreements allow up to 1,833,344 share repurchases from holders; further public offerings possible until June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108713,"accession_number":"0001193125-26-102153","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Q4 revenue $397.6M (+17% YoY), net income $21.3M (+81%); raises 2026 EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 diluted EPS $0.33, adjusted EPS $0.37; full-year diluted EPS $0.78, adjusted EPS $1.07.","Full-year revenue $1.45B (+18% YoY); net income $49.0M vs $71.0M loss in 2024.","2026 Adjusted EBITDA guidance raised to $120M–$124M (from $115M–$118M); revenue guidance unchanged $1.40B–$1.42B.","Cash $65.6M at year-end, no long-term debt outstanding under $75M credit facility.","Annualized return on equity approximately 27% in 2025; 54 full-service pharmacies after North Ridge acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108712,"accession_number":"0001193125-26-011826","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardian reiterates 2025 guidance, provides 2026 outlook with ~11% adj. EBITDA growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reaffirmed 2025 revenue $1.43B-$1.45B and adjusted EBITDA $104M-$106M.","2026 outlook: revenue $1.40B-$1.42B (down due to IRA drug price cuts) and adjusted EBITDA $115M-$118M.","2026 adjusted EBITDA margin expected above 8%, structural improvement from 2025.","Completed year-end acquisition of a single pharmacy in Montana, adding new territory.","CEO expects low double-digit adjusted EBITDA growth despite mandatory price reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1448685000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125169,"accession_number":"0001193125-25-274250","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Q3 revenue up 20% YoY to $377.4M; raises full-year revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $377.4M (+20% YoY); residents served ~204,000 (+13% YoY).","Net income $9.6M vs $(105.8)M prior (not comparable); Adjusted EBITDA $27.3M vs $23.0M prior.","Diluted EPS $0.15; Adjusted EPS $0.25.","Raised FY2025 guidance: revenue $1.43B-$1.45B (prev $1.39B-$1.41B), Adj. EBITDA $104M-$106M (prev $100M-$102M).","Acquired Managed Healthcare Pharmacy in Oregon; lock-up agreements on ~93% of shares through June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1051069000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125168,"accession_number":"0001193125-25-239120","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Guardian Pharmacy extends lock-up on ~93% of pre-IPO shares through June 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lock-up agreements cover ~93% of shares held by founders, executives, and pre-IPO holders, extending restrictions from Oct 19, 2025 to June 30, 2026.","Restrictions apply to 17.2M Class A shares outstanding and 12.8M Class A shares issuable upon Class B conversion in March 2026.","As of Sept 30, 2025, company had 36.3M Class A and 27.1M Class B shares outstanding.","Lock-up holders cannot sell or transfer without company consent; period can be extended by mutual agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141885,"accession_number":"0001193125-25-206771","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Guardian Pharmacy posts investor presentation; no specific financial or operational updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a presentation for use in investor meetings.","Presentation covers business overview; no new financial data or guidance provided.","No material changes or events disclosed in the filing text or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141884,"accession_number":"0001193125-25-177963","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Q2 revenue up 15%, raises FY guidance; Adj EBITDA $25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $344.3M, +15% YoY; resident count >195,000 (+12% YoY).","Net income $8.8M (vs $15.8M prior) due to $3.8M tax, $4.7M stock comp; Adj EBITDA $25.0M vs $21.7M.","Diluted EPS $0.14, Adjusted EPS $0.23; cash $18.8M, no long-term debt.","Full-year guidance raised: Revenue $1.39B-$1.41B (prev $1.33B-$1.35B); Adj EBITDA $100M-$102M (prev $97M-$101M).","Acquired pharmacies in Wichita, KS and Seattle, WA; subsequent Aug 4 acquisition of Managed Healthcare Pharmacy in Oregon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":673642000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159815,"accession_number":"0001193125-25-142451","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Guardian Pharmacy holds Investor Day; presentation details unavailable in extracted text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day conducted on June 18, 2025; presentation made available to investors.","Filing states presentation contains financial highlights and business information.","Extracted exhibit text only includes title page and disclaimer; no specific data available.","No new financial guidance, earnings, or material events reported in the provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159814,"accession_number":"0001193125-25-123145","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Guardian Pharmacy to buy up to 1.46M shares from holders in synthetic secondary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to purchase up to 1,457,365 shares of Class A common stock from certain holders.","Purchase price per share equals public offering price less underwriting discount.","Proceeds from concurrent public offering will fund the repurchase.","Holders subject to 150-day lock-up after underwriting agreement; prior lock-up terminated.","Closing conditioned on consummation of the public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159813,"accession_number":"0001193125-25-117815","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guardian Pharmacy holds 2025 annual meeting; elects three directors, ratifies EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected David Morris, Mary Sue Patchett, and Thomas Salentine as Class I directors.","Ratified appointment of Ernst & Young LLP as independent auditor for 2025 with 45,640,998 votes for.","Broker non-votes of 485,295 on director elections due to discretionary voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159812,"accession_number":"0001193125-25-117795","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Q1 rev $329.3M (+20% YoY), net income $9.3M, Adj EBITDA $23.4M, reaffirms FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $329.3M (+20% YoY); resident count 189K (+15% YoY) driven by organic growth and acquisitions.","Net income $9.3M (+$2.2M YoY); Adjusted EBITDA $23.4M (+16% YoY) after ~$1.0M public company costs.","Closed small acquisition in Wichita, KS on April 1, 2025; total pharmacies now 52.","Reaffirmed FY2025 guidance: revenue $1.330B-$1.350B, Adj EBITDA $97M-$101M; expects revenue near upper end.","No long-term debt; cash $14.0M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":329308000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178182,"accession_number":"0001193125-25-067044","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardian Pharmacy sets 2025 incentive targets: revenue, Adj. EBITDA, geographic expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Fred Burke target award $278,100; threshold $208,575; maximum $347,625.","CFO David Morris target $247,200; EVP Kendall Forbes target $247,200.","Metrics: revenue (20% weight), Adjusted EBITDA (60%), geographic expansion (20%).","Payout ranges from 75% of target at threshold to 125% at maximum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178181,"accession_number":"0001193125-25-064079","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Q4 revenue up 20% to $338.6M; FY net loss $71M on IPO charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $338.6M (+20% YoY); resident count 186,000 (+14% YoY).","Q4 net income $11.8M (down $2.7M YoY); FY net loss $71.0M on $131.5M stock-comp from IPO/Reorg.","Adjusted EBITDA Q4 $25.9M (+30% YoY); FY $90.8M (+19% YoY).","No debt outstanding at year-end; $40M credit line available (expandable to $75M).","FY2025 guidance: revenue $1.33B-$1.35B, Adj. EBITDA $97M-$101M; incl. ~$4M public co. costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178180,"accession_number":"0001193125-25-043339","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardian Pharmacy reports preliminary Q4 revenue up 20.5% YoY, adj EBITDA up 30.3%; provides FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$338.6M, +20.5% YoY; net income $10.1-11.1M; adjusted EBITDA ~$25.9M, +30.3% YoY.","FY2024 revenue ~$1.228B (+17.4% YoY); adjusted EBITDA ~$90.8M (+19.2% YoY); net loss ($71.8M-$72.8M) due to $131.5M IPO-related share-based comp.","FY2025 guidance: revenue $1.33-1.35B, adjusted EBITDA $97-101M; conference call March 26, 2025.","Resident count ~186,000 at Q4 end, +14.1% YoY from organic growth and acquisitions.","Acquisitions of Heartland Pharmacy (Apr 2024) and Freedom Pharmacy (Nov 2024) contributed to growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178179,"accession_number":"0001193125-25-024341","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardian Pharmacy grants $240k RSUs to CFO & EVP; pays 100% of 2024 cash incentives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["RSU awards of $240,000 each to CFO David Morris and EVP Kendall Forbes, vesting fully on Feb 5, 2028.","CEO Fred Burke requested no additional equity awards due to existing ownership.","2024 annual cash incentive payouts at 100% target: CEO $270k, CFO $240k, EVP $240k."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194845,"accession_number":"0001193125-24-283106","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Guardian Pharmacy Services assumes borrower role under existing credit facility from subsidiary","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["GRDN becomes primary borrower under Third Amended and Restated Loan and Security Agreement with Regions Bank as agent, effective December 20, 2024.","Grants security interest in all real and personal property, plus equity interests of wholly owned and non-wholly owned subsidiaries to secure existing obligations.","Guardian Pharmacy, LLC shifts from borrower to guarantor; all existing subsidiary guarantors reaffirm their guarantee.","No changes to loan terms, interest rate, maturity, or outstanding principal amount disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194844,"accession_number":"0001193125-24-255981","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Q3 revenue $314M (+20% YoY); Adj. EBITDA $23M (+20%); guides FY24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $314.4M (+20% YoY) driven by organic growth and Heartland Pharmacy acquisition.","Net loss of $105.8M due to $122.4M share-based comp from IPO; Adj. EBITDA of $23.0M (+20% YoY).","Resident count of 180,000 at quarter-end, up 12% YoY.","FY 2024 guidance: revenue $1.205B-$1.215B, Adjusted EBITDA $86.5M-$87.0M.","Completed a small acquisition in Q3, entering a new market with a strong operating team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":889840000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211138,"accession_number":"0001193125-24-228997","cik":1802255,"company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","5.02","9.01"],"status":"ready","headline":"Guardian Pharmacy Services closes IPO of 9.2M shares; adopts new governance structure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO on Sept 27, 2024; sold 8M Class A shares; underwriters exercised option for 1.2M additional shares.","Completed corporate reorganization; issued 54,094,132 Class B shares to former LLC members.","Stockholders' Agreement grants nomination rights to Bindley Capital, Cardinal, and founders; board expanded to eight with classified structure.","Adopted 2024 Equity Incentive Plan; employment agreements with CEO Fred Burke ($450K base), CFO David Morris, and EVP Kendall Forbes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2472037497.390593,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}